Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting in Children with Cancer

被引：11

作者：

Cefalo, M. G. ^{[1
]}

Ruggiero, A. ^{[1
]}

Maurizi, P. ^{[1
]}

Attina, G. ^{[1
]}

Arlotta, A. ^{[1
]}

Riccardi, R. ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Div Pediat Oncol, I-00168 Rome, Italy

来源：

JOURNAL OF CHEMOTHERAPY | 2009年 / 21卷 / 06期

关键词：

Nausea; vomiting; chemotherapy; children; antiemetic agents; MODERATELY EMETOGENIC CHEMOTHERAPY; CISPLATIN-INDUCED EMESIS; ANTIEMETIC THERAPY; DOUBLE-BLIND; NEUROKININ-1; ANTAGONIST; PEDIATRIC ONCOLOGY; PHASE-III; APREPITANT; PREVENTION; ONDANSETRON;

D O I：

10.1179/joc.2009.21.6.605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nausea and vomiting are respectively the first and third most relevant chemotherapy-associated side effects in pediatric oncology, despite the introduction of new antiemetic agents. Symptoms change according to the antineoplastic agents used, and are influenced by age since emotional and psychological aspects play an important role. Studies conducted on new antiemetic therapies usually focus on adult populations affected by tumors, whereas there are very few series including pediatric patients, who are even more severely affected by this specific side effect.

引用

页码：605 / 610

页数：6

共 47 条

[1] Granisetron: An update on its clinical use in the management of nausea and vomiting [J].

Aapro, M .

ONCOLOGIST, 2004, 9 (06) :673-686

[2] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [J].

Aapro, M. S. ;

Grunberg, S. M. ;

Manikhas, G. M. ;

Olivares, G. ;

Suarez, T. ;

Tjulandin, S. A. ;

Bertoli, L. F. ;

Yunus, F. ;

Morrica, B. ;

Lordick, F. ;

Macciocchi, A. .

ANNALS OF ONCOLOGY, 2006, 17 (09) :1441-1449

[3] Anticipatory nausea and vomiting [J].

Aapro, MS ;

Molassiotis, A ;

Olver, I .

SUPPORTIVE CARE IN CANCER, 2005, 13 (02) :117-121

[4]

[Anonymous], 2009, Common Terminology Criteria for Adverse Events (CTCAE). 4.0 ed

[5] Use of Acupuncture in the Control of Chemotherapy-Induced Nausea and Vomiting [J].

Bao, Ting .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (05) :606-612

[6]

Bender Catherine M, 2002, Clin J Oncol Nurs, V6, P94, DOI 10.1188/02.CJON.94-102

[7] Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone [J].

Campos, D ;

Pereira, JR ;

Reinhardt, RR ;

Carracedo, C ;

Poli, S ;

Vogel, C ;

Martinez-Cedillo, J ;

Erazo, A ;

Wittreich, J ;

Eriksson, LO ;

Carides, AD ;

Gertz, BJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1759-1767

[8] Tropisetron: Optimal dosage for children in prevention of chemotherapy-induced vomiting [J].

Cappelli, C ;

Ragni, G ;

De Pasquale, MD ;

Gonfiantini, M ;

Russo, D ;

Clerico, A .

PEDIATRIC BLOOD & CANCER, 2005, 45 (01) :48-53

[9] Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis [J].

Cocquyt, V ;

Van Belie, S ;

Reinhardt, RR ;

Decramer, MLA ;

O'Brien, M ;

Schellens, JHM ;

Borms, M ;

Verbeke, L ;

Van Aelst, F ;

De Smet, M ;

Carides, AD ;

Eldridge, K ;

Gertz, BJ .

EUROPEAN JOURNAL OF CANCER, 2001, 37 (07) :835-842

[10] Ondansetron: A review of its use as an antiemetic in children [J].

Culy C.R. ;

Bhana N. ;

Plosker G.L. .

Paediatric Drugs, 2001, 3 (6) :441-479

← 1 2 3 4 5 →